# Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Study · id `cardio:ct-nct04811092` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04811092](<https://clinicaltrials.gov/study/NCT04811092>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04811092

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 321 participants.

## Technical summary

Registry record NCT04811092. Randomized; double masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2025-04-03 (actual). Results posted on 2026-04-27.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 321 participants (enrolled count; ClinicalTrials.gov record NCT04811092, source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)
- Started: 2022-03-18 (actual) (ClinicalTrials.gov record NCT04811092, source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)
- Primary completion: 2025-04-03 (actual) (ClinicalTrials.gov record NCT04811092, source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)
- Completion: 2025-04-03 (actual) (ClinicalTrials.gov record NCT04811092, source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)
- Results first posted: 2026-04-27 (ClinicalTrials.gov record NCT04811092, source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Colombia; Croatia; Czechia; Denmark; France; Germany; Greece; Israel; Italy; Netherlands; New Zealand; Poland; Portugal; Serbia; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT04811092, source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04811092-2026-06-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
- Acronym: HYPERION
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Sotatercept
- Intervention (Other): Placebo
- Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (`cardio:org-acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-341e98`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis (`cardio:pubmed-41025556`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a56c86c828f046f32f48134e647c3bd0fc743210c40f7c868a42ddc24bcc767b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
